Vemurafenib

84 interactions 6 explained in plain English

Also sold as: Zelboraf Zelboraf®

About Vemurafenib

Vemurafenib is used to treat certain types of melanoma (a type of skin cancer) that cannot be treated with surgery or that has spread to other parts of the body. It is also used to treat a certain type of Erdheim-Chester disease (ECD; a disease that causes an overproduction of a type of white blood cells). Vemurafenib… Read the full Vemurafenib drug information page →

Medically reviewed by Dr. Brian Staiger, PharmD, BCPS · Updated Jun 30, 2026 · Editorial policy · Data sources

Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →

Most serious with: Colchicine Ketoconazole Topical Afatinib Oxaliplatin Injection Atogepant Cariprazine

2 Contraindicated 80 Major 2 Moderate

All (84) Contraindicated (2) Major (80) Moderate (2)

Contraindicated

Vemurafenib Colchicine Colcrys Explained Increased colchicine exposure and an increased risk of colchicine toxicity Details Vemurafenib Ketoconazole Topical Extina® Foam Increased vemurafenib exposure and an increased risk of QT interval prolongation Details

Major

Vemurafenib Amitriptyline Elavil Explained Increased risk of QT interval prolongation Details Vemurafenib Sertraline Explained An increased risk of QT interval prolongation Details Vemurafenib Buprenorphine Belbuca Explained An increased risk of QT interval prolongation Details Vemurafenib Relugolix Orgovyx Explained Increased relugolix exposure and an increased risk of QT interval prolongation Details Vemurafenib Amisulpride Injection Barhemsys Increased risk of serious ventricular arrhythmias such as torsades de pointes Details Vemurafenib Arsenic Trioxide Trisenox Increased risk of QT interval prolongation Details Vemurafenib Aripiprazole Injection Abilify Increased risk of QT interval prolongation Details Vemurafenib Arsenic Trioxide Injection Trisenox Increased risk of QT interval prolongation Details Vemurafenib Asenapine Transdermal Patch Secuado Increased risk of QT interval prolongation Details Vemurafenib Atogepant Qulipta Reduced atogepant exposure Details Vemurafenib Azithromycin AzaSite Increased risk of QT interval prolongation Details Vemurafenib Betrixaban Bevyxxa® Increased betrixaban exposure and increased risk of bleeding Details Vemurafenib Cariprazine Vraylar Explained Effects on the cariprazine exposure has not been evaluated and the net effect is unclear Details Vemurafenib Afatinib Gilotrif Increased exposure of afatinib Details Vemurafenib Alfuzosin UroXatral Increased risk of QT interval prolongation Details Vemurafenib Amlodipine Amvaz® Reduced amLODIPine exposure Details Vemurafenib Anagrelide Agrylin Increased risk of QT interval prolongation Details Vemurafenib Bedaquiline Sirturo Increased risk of QT interval prolongation Details Vemurafenib Bendamustine Injection Belrapzo Increased bendamustine exposure and an increased risk of bendamustine-related adverse effects Details Vemurafenib Chloroquine Aralen® Increased risk of QT interval prolongation Details Vemurafenib Cyclosporine Injection Atopica Increased cycloSPORINE exposure Details Vemurafenib Cyclosporine Ophthalmic Cequa Increased cycloSPORINE exposure Details Vemurafenib Dabigatran Pradaxa® Increased dabigatran exposure and an increased risk of bleeding Details Vemurafenib Dabigatran Etexilate Increased dabigatran exposure and an increased risk of bleeding Details Vemurafenib Dasatinib Phyrago Increased risk of QT interval prolongation Details Vemurafenib Degarelix Injection Firmagon Increased risk of QT-interval prolongation Details Vemurafenib Deutetrabenazine Austedo An increased risk of QT interval prolongation Details Vemurafenib Digoxin Cardoxin® Increased digoxin exposure Details Vemurafenib Disopyramide Norpace Increased risk of QT interval prolongation Details Vemurafenib Dofetilide Tikosyn Increased risk of QT interval prolongation Details Vemurafenib Dolasetron Anzemet Increased risk of QT interval prolongation Details Vemurafenib Dolasetron Injection Anzemet Increased risk of QT interval prolongation Details Vemurafenib Doxorubicin Adriamycin Increased DOXOrubicin exposure and an increased risk of DOXOrubicin-related adverse reactions Details Vemurafenib Encorafenib Braftovi Increased risk of QT interval prolongation Details Vemurafenib Entrectinib Rozlytrek An increased risk of QT interval prolongation Details Vemurafenib Eribulin Injection Halaven Increased risk of QT interval prolongation Details Vemurafenib Famotidine Calmicid Increased risk of QT interval prolongation Details Vemurafenib Famotidine Injection Calmicid Increased risk of QT interval prolongation Details

Check another drug

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist

Educational information only, not medical advice. Always confirm interactions with your pharmacist or prescriber before making any change to your medications.